



EU-HTA

Impact for the Statutory Health Insurance (SHI)


13.11.2023 | Copenhagen | ISPOR Europe 2023

Dr. Lutz Herbarth, MBA

Results of benefit assessments affect all SHI in the same way, they are not directly involved in decisions



Distribution of SHI insured persons across types of health insurance



Versicherte

vdek	28.459.619
AOK	27.525.704
BKK	11.168.736
IKK	5.158.096
KBS	1.429.675
LKK	529.216
GKV	74.271.046

KKH Kaufmännische Krankenkasse



Founded as Health insurance for commercial professions 1890

Insured: 1.6 million

Budget volume: 6,7 billion Euro

Employees: 3800 nationwide

Headquarter: Hannover

The SHI association (GKV-SV) expresses concerns about the EU-HTA procedure

Examples:

- ⚡ Differences in key areas relevant to Germany's decision-making, such as the selection of comparators and the assessment of the patient relevance of end points directly influence the reliability and relevance of the conclusions and thus their usability at the national level.
- ⚡ Endorsement of voluntary and consensus-based cooperation between national HTA agencies, which should only be supported administratively by the EU Commission.
- ⚡ Demand for methods and processes for the joint clinical assessments beeing determined by the member states and the HTA organizations and not by delegated legal acts or implementing acts of the EU Commission.
- ⚡ No mandatory adoption of joint clinical assessments by the Member States and no a ban on their own assessments, as this would affect national decision-making systems and patient care.
- 🕒 The cooperation in horizon scanning provides results of which enable the selection of the assessment items and provides information of budgetary effects, makes sense.

No relevance for the individual health insurance company so far?

For operational SHI business, yes

.....but some aspects of the EU-HTA are of interest for SHI

Areas in which the EU-HTA can influence the work of a SHI

SHI in Germany are indirectly affected by the EU-HTA in particular through the possible effects on the reimbursement of health technologies and medicines.

It requires the harmonization of national laws and procedural regulations with the EU-HTA to have an immediate impact on the SHI.



Reimbursement
and
Care
Contracts



Cost-benefit
assessment



Access to
innovative
therapies



Quality and
relevance of
the
endpoints
and study
designs

**Vielen Dank für die
Aufmerksamkeit!**

**Thank you for your
attention**

Dr. Lutz Herbarth, MBA

Care Management, Contracts and Pharmaceuticals

E-Mail:

Lutz.herbarth@kkh.de

Telefon:

+49 151 74545192